The Institute for Clinical and Economic Review (ICER) on Tuesday released an Evidence Report assessing the comparative clinical effectiveness and value of three vesicular monoamine transporter-2 (VMAT2) inhibitors for management of tardive dyskinesia (TD), a movement disorder often associated with long-term use of certain antipsychotic drugs.
The report reviews evidence on valbenazine (Ingrezza, Neurocrine Biosciences) and deutetrabenazine (Austedo, Teva), both approved earlier this year for treatment of TD, as well as tetrabenazine (Xenazine, Lundbeck), which is approved for use in Huntington’s disease but has also been used to treat TD.
This Evidence Report will be the subject of a Dec. 7 public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in Newton, Mass. The New England CEPAC is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
“While the evidence is promising, uncertainty remains around the true spectrum of clinical benefit and long-term safety with these treatments, and current prices are far out of alignment with the benefits measured in clinical trials,” ICER Chief Scientific Officer Dan Ollendorf said.